Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Strip out the Covid product gains and Pfizer’s predicament is unchanged. It is struggling to convince investors there is life ...

Pfizer in September recalled the sickle cell anemia treatment Oxbryta due to safety concerns. The drug was gained in the 2022 purchase of Global Blood Therapeutics Inc. for $5.4 billion.